Latest News-Dizal (Jiangsu) Pharmaceutical Company Limited Mediaroom_Page

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal...

2023-12-13 18:00 2120

Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio o...

2023-12-12 18:00 2148

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory...

2023-12-10 18:00 2434

Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients

* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in th...

2023-10-23 17:34 1683

Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Prod...

2023-09-21 20:26 2003

Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation ...

2023-09-14 17:07 2006

Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology

SHANGHAI, Sept. 10, 2023 /PRNewswire/ -- Dizal today announced the publication of the Phase I clini...

2023-09-10 17:03 2392

Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations

* Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first C...

2023-08-23 19:21 1291

2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib

* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctD...

2023-08-17 17:10 2577

Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting

SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncolog...

2023-05-26 06:00 2650

Dizal's Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting

Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presenta...

2023-04-27 07:20 2399

Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Dr...

2023-01-10 17:03 2733

Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

* The confirmed objective response (cORR), as assessed by blinded independent central review (BIC...

2022-09-05 22:49 3057

Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO

PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data f...

2022-09-05 22:39 2857

Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022

Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion ...

2022-05-27 18:00 1981

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing ph...

2022-05-13 19:09 3054

FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion

SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), tod...

2022-01-27 21:15 4198